AmpliMed Corporation
Innovative oncology therapies paving the way for advanced cancer treatment
Innovative oncology therapies paving the way for advanced cancer treatment
AmpliMed Corporation is a biotechnology company that focuses on developing small-molecule drugs for cancer treatment. Their flagship product, Amplimexon, has demonstrated the ability to stop the division of cancer cells, ultimately leading to their demise. Additionally, Amplizone, another key product, has shown promise in combatting solid tumors in animal models. The company's research and development also includes benzimidazole analog small molecules designed to treat various cancers such as pancreatic, lung, malignant melanoma, ovarian cancer, and multiple myeloma. Established in 1989 and headquartered in Tucson, Arizona, AmpliMed Corporation garnered a $7.14M Venture Round investment on 03 March 2010.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $7.14M | - | 03 Mar 2010 | |
| Debt Financing | $2.00M | - | 30 Apr 2009 | |
| Series C | $5.00M | 4 |
|
14 Jan 2008 |
| Series B | $5.00M | 3 |
|
16 Jun 2005 |
| Series A | $4.25M | 3 |
|
11 May 2004 |
No recent news or press coverage available for AmpliMed Corporation.
We care about your data, and we'd love to use cookies make your experience better.